Jci_page_head_homepage_01 Jci_page_head_homepage_02
Honglin Wang, Thorsten Peters, Anca Sindrilaru, Daniel Kess, Tsvetelina Oreshkova, Xue-Zhong Yu, Anne Maria Seier, Heike Schreiber, Meinhard Wlaschek, Robert Blakytny, Jan Röhrbein, Guido Schulz, Johannes M. Weiss, Karin Scharffetter-Kochanek
Published in Volume 118, Issue 7
J Clin Invest. 2008; 118(7):2629–2639 doi:10.1172/JCI34916
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 1
Adoptive transfer of Cd18wt CD4+CD25+CD127 Tregs into affected Cd18hypo mice resolves the psoriasiform skin disease.

(A) Representative clinical pictures of a Cd18hypo mouse with severe psoriasiform skin disease before (left panel) and almost complete resolution 42 days after the first adoptive transfer with Tregs from Cd18wt mice (right panel). An adapted PASI score was used to assess the severity of the psoriasiform phenotype before and after adoptive transfer with Cd18wt Tregs (B) or Cd18hypo Tregs (C). Data are representative of 3 independent experiments. (D) An improvement of the psoriasiform skin disease in affected Cd18hypo mice was observed after intradermal injection of Cd18wt Tregs once weekly for 3 weeks. (E and F) The adapted PASI score of affected Cd18hypo mice treated with Cd18wt Tregs is significantly reduced compared with that of mice treated with Cd18hypo Tregs. **P < 0.01, using Student’s t test. Original magnification, × 1 (A and D).